Is IMRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IMRX. It does not provide personalized investment advice.

IMRX (Immuneering Corporation Class A Common Stock) Stock Analysis - Financials

Immuneering Corporation Class A Common Stock (IMRX) is a publicly traded Healthcare sector company. As of October 26, 2026, IMRX trades at $3.66 with a market cap of $241.32M and a P/E ratio of -3.22. IMRX moved +0.00% today. Year to date, IMRX is -43.31%; over the trailing twelve months it is -33.75%. Its 52-week range spans $1.10 to $10.08. Analyst consensus is strong buy with an average price target of $14.00. Rallies surfaces IMRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are IMRX's key financials?

IMRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. IMRX recently traded at $3.66. Market cap is $241.32M. P/E ratio is -3.22. Revenue is $0.

IMRX Key Metrics

Key financial metrics for IMRX
Metric	Value
Price	$3.66
Market Cap	$241.32M
P/E Ratio	-3.22
EPS	$-1.27
Dividend Yield	0.00%
52-Week High	$10.08
52-Week Low	$1.10
Volume	40.56K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-56.02M
Gross Margin	0.00%

IMRX Analyst Consensus

4 analysts cover IMRX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.00.

Common questions about IMRX

What are IMRX's key financials?: IMRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. IMRX recently traded at $3.66. Market cap is $241.32M. P/E ratio is -3.22. Revenue is $0.
Is IMRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IMRX. It does not provide personalized investment advice.